|
|
VSA-1 |
|
Vaxjo ID |
206 |
|
Vaccine Adjuvant Name |
VSA-1 |
|
Adjuvant VO ID |
VO_0005326
|
|
Description |
A vaccine adjuvant that is prepared by derivatizing a natural Momordica saponin in one chemical step. VSA-1 is chemically more stable than QS-21. VSA-1 is much less toxic than QS-21. The Momordica saponins are from sustainable sources and widely available |
|
Stage of Development |
Research |
|
Location Licensed |
US (U of Alabama:Birmingham) |
|
Host Species for Testing |
Mouse |
|
Components |
Momordica saponins |
|
Storage |
4C |
|
Preparation |
saponins isolated using the published procedure (https://www.jstage.jst.go.jp/article/cpb1958/33/2/33_2_464/_article/-char/ja/) |
|
Function |
Type: synthetic vaccine adjuvant. Induces Th1/Th2 mixed immune profile. potentiates antigen specific responses boosting IgG, IgG1 and IgG2a antibodies. It induces a mixed Th1/Th2 response and boosts CTL activity |
|
Safety |
much less toxic than QS21 |
| References |
(Wang, 2025): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=41]
Bai et al., 2024: Bai D, Kim H, Wang P. Development of semisynthetic saponin immunostimulants. Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents. 2024; 33(8); 1292-1306. [PubMed: 39132259].
Wang et al., 2019: Wang P, Ding X, Kim H, Å kalamera Ä, Michalek SM, Zhang P. Vaccine Adjuvants Derivatized from Momordica Saponins I and II. Journal of medicinal chemistry. 2019; 62(21); 9976-9982. [PubMed: 31657920].
|
|
